![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients...
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during...
-Enrolled patients allowed to continue on study- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.33 | 12.7906976744 | 2.58 | 3.07 | 2.49 | 130242 | 2.83763205 | CS |
4 | 0.82 | 39.2344497608 | 2.09 | 3.07 | 2.02 | 167890 | 2.59708174 | CS |
12 | 0.57 | 24.358974359 | 2.34 | 3.07 | 1.91 | 145051 | 2.31211571 | CS |
26 | -15.72 | -84.3800322061 | 18.63 | 21.4 | 1.91 | 320070 | 3.77068885 | CS |
52 | -4.93 | -62.8826530612 | 7.84 | 22.22 | 1.91 | 196194 | 6.28440657 | CS |
156 | -13.94 | -82.7299703264 | 16.85 | 23.58 | 1.91 | 119243 | 7.69911986 | CS |
260 | -13.94 | -82.7299703264 | 16.85 | 23.58 | 1.91 | 119243 | 7.69911986 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions